Figure 4.
Volagidemab binds the glucagon receptor to prevent glucagon binding, which inhibits glycogenolysis and gluconeogenesis. It also increases alpha-cell mass and allows excess alpha cells to be transdifferentiated to beta cells.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.